Senti Bio Q2 2025 net loss $14.7M; completes dose finding for SENTI-202 AML trial, RP2D confirmed

Senti Biosciences, Inc.

2025-Q2 EPS reported -$1.59 vs consensus -$0.92 ▼ miss (-73.2%)

Net loss of $14.7M ($0.56 per share); cash $21.6M as of June 30, 2025, down from $48.3M at Dec 31, 2024.
Completed dose finding and confirmed RP2D for Phase 1 SENTI-202 trial in AML; now in dose expansion.
Received FDA Orphan Drug Designation for SENTI-202 in AML.
Received $1.0M from CIRM grant; added Bryan Baum to Board, Dr. James Trager to Scientific Advisory Board.
Expect additional efficacy and durability data from SENTI-202 Phase 1 study in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.